Stem cell-derived nodal-like cardiomyocytes as a novel pharmacologic tool: insights from sinoatrial node development and function.
Since the first reports on the isolation and differentiation of stem cells, and in particular since the early success in driving these cells down a cardiac lineage, there has been interest in the potential of such preparations in cardiac regenerative therapy. Much of the focus of such research has been on improving mechanical function after myocardial infarction; however, electrophysiologic studies of these preparations have revealed a heterogeneous mix of action potential characteristics, including some described as "pacemaker" or "nodal-like," which in turn led to interest in the therapeutic potential of these preparations in the treatment of rhythm disorders; several proof-of-concept studies have used these cells to create a biologic alternative to electronic pacemakers. Further, there are additional potential applications of a preparation of pacemaker cells derived from stem cells, for example, in high-throughput screens of new chronotropic agents. All such applications require reasonably efficient methods for selecting or enriching the "nodal-like" cells, however, which in turn depends on first defining what constitutes a nodal-like cell since not all pacemaking cells are necessarily of nodal lineage. This review discusses the current state of the field in terms of characterizing sinoatrial-like cardiomyocytes derived from embryonic and induced pluripotent stem cells, markers that might be appropriate based on the current knowledge of the gene program leading to sinoatrial node development, what functional characteristics might be expected and desired based on studies of the sinoatrial node, and recent efforts at enrichment and selection of nodal-like cells.
Department of Biosciences, Università degli Studi di Milano, Milano, Italy (A.B.); and Department of Pharmacology, Columbia University Medical Center, New York, New York (R.B.R.).
Andrea
A
Barbuti
Department of Biosciences, Università degli Studi di Milano, Milano, Italy (A.B.); and Department of Pharmacology, Columbia University Medical Center, New York, New York (R.B.R.) rbr1@columbia.edu.
Richard B
RB
Robinson
D000818:Animals; D001146:Arrhythmia, Sinus / Q000503:physiopathology / Q000628:therapy*; D001341:Autonomic Nervous System / Q000502:physiology / Q000503:physiopathology; D035843:Biomedical Research / Q000639:trends; D002316:Cardiotonic Agents / Q000494:pharmacology; D002454:Cell Differentiation; D053595:Embryonic Stem Cells / Q000166:cytology*; D057166:High-Throughput Screening Assays / Q000639:trends; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology*; D008954:Models, Biological; D032383:Myocytes, Cardiac / Q000166:cytology* / Q000187:drug effects / Q000502:physiology / Q000637:transplantation; D044968:Regenerative Medicine / Q000379:methods / Q000639:trends; D012849:Sinoatrial Node / Q000166:cytology* / Q000196:embryology / Q000294:innervation / Q000502:physiology; D033581:Stem Cell Transplantation
D002316:Cardiotonic Agents